Clinical Trial News and Research

RSS

AHA/ASA identify top cardiovascular and stroke research advances for 2012

Resuscitation, cell regeneration, a new high blood pressure treatment and developments in devices for treating stroke are among the key scientific findings that make up this year's top cardiovascular and stroke research identified by the American Heart Association and American Stroke Association.

18 Dec 2012

University of Leicester autism expert contributes to international global health study

A leading international expert on autism at the University of Leicester has been involved in contributing to a major new study of global health.

18 Dec 2012

Tbx18 gene directs conversion of cardiomyocytes to genuine pacemaker cells

Cedars-Sinai Heart Institute researchers have reprogrammed ordinary heart cells to become exact replicas of highly specialized pacemaker cells by injecting a single gene (Tbx18)-a major step forward in the decade-long search for a biological therapy to correct erratic and failing heartbeats.

18 Dec 2012

Study sheds light on how new treatments could be more effective in early stages of bipolar disorder

A North West clinical trial of people who have been diagnosed with bipolar disorder for less than five years will be the first study of its kind to shed light on how new treatments could be more effective in the early stages of the condition.

17 Dec 2012

Lexicon receives FDA Fast Track status for development of LX1033 for irritable bowel syndrome

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has received "Fast Track" status from the U.S. Food and Drug Administration for the development of LX1033, an orally-delivered small molecule drug candidate for diarrhea-predominant irritable bowel syndrome (IBS-d).

17 Dec 2012

UMCG enrolls and treats first patients in RENEW pivotal trial to evaluate RePneu LVRC

PneumRx, Inc., a leader in interventional pulmonology, announced today that University Medical Center Groningen has enrolled and treated the first patients in the FDA-approved RENEW pivotal trial to evaluate the RePneu Lung Volume Reduction Coil.

17 Dec 2012

IRB Barcelona, BBVA Foundation organize international conference on biostatistics

Statistics have entered the life sciences and they are here to stay. This science emerged in the XVIII century by the hand of the mathematicians Thomas Bayes and Pierre Simon Laplace and was used by Gregor Mendel to demonstrate his theory on genetic inheritance. Since the 90s with the appearance of large genomic studies, statistics has become a fundamental tool for the analysis and interpretation of biomedical data.

16 Dec 2012

AcelRx announces top-line data from Sufentanil NanoTab PCA System Phase 3 trial

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that top-line data from its previously announced open-label, active-comparator study of its lead product candidate, the Sufentanil NanoTab PCA System, will be featured in poster presentations to be held at the 66th annual New York State Society of Anesthesiologists PostGraduate Assembly meeting in New York City to be held December 14-18, 2012.

15 Dec 2012

Novartis receives FDA approval for Signifor injection to treat Cushing's disease

The U.S. Food and Drug Administration today approved Signifor (pasireotide diaspartate) injection for the treatment of Cushing's disease patients who cannot be helped through surgery.

15 Dec 2012

Cempra commences CEM-102 Phase 2 trial in prosthetic joint infections

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced the initiation of its Phase 2 clinical trial of CEM-102 in patients with prosthetic joint infections (PJIs).

15 Dec 2012

Iclusig gets FDA approval for two rare blood and bone marrow diseases

The U.S. Food and Drug Administration today approved Iclusig (ponatinib) to treat adults with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases.

15 Dec 2012

CEL-SCI net loss decreases to $17.6 million for fiscal year 2012

CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2012.

14 Dec 2012

FDA approves Novartis Signifor injection for treatment of Cushing's disease

Novartis announced today that the US Food and Drug Administration (FDA) has approved Signifor (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.

14 Dec 2012

God will control my asthma

Research shows that patients’ belief in God influences how likely they are to be adherent to asthma medication.

14 Dec 2012

NovaDigm announces data from NDV-3 vaccine Phase 1 study on Candida and Staph infections

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the publication of data from its first-in-human Phase 1 study of its NDV-3 vaccine program in the journal Vaccine.

13 Dec 2012

Diuretic-based antihypertensive therapy touted for obese

Diuretic-based antihypertensive regimens may be preferable to calcium channel blocker-based therapy in patients who are obese, suggest researchers writing in The Lancet.

13 Dec 2012

Doctors should use different therapies when treating older and younger patients with CLL

Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).

13 Dec 2012

Eli Lilly provides update on solanezumab Phase 3 clinical study for mild Alzheimer's

Eli Lilly and Company today provided an update on the next steps planned for solanezumab, its Phase 3 monoclonal antibody being studied as a potential therapy for patients with mild Alzheimer's disease.

13 Dec 2012

Bumetanide could treat children with severe autism or Asperger's syndrome

Although this therapy is not curative, it nevertheless reduced the autistic disorders' severity in three-quarters of the children. The researchers have filed a request for authorisation to perform a multi-centre European clinical trial in order to determine more precisely the population concerned by this therapy.

13 Dec 2012

AZD6765 briefly improves treatment-resistant patients' depression symptoms in minutes

A drug that works through the same brain mechanism as the fast-acting antidepressant ketamine briefly improved treatment-resistant patients' depression symptoms in minutes, with minimal untoward side effects, in a clinical trial conducted by the National Institutes of Health. The experimental agent, called AZD6765, acts through the brain's glutamate chemical messenger system.

13 Dec 2012

Clinical Trial News and Research

AHA/ASA identify top cardiovascular and stroke research advances for 2012

University of Leicester autism expert contributes to international global health study

Tbx18 gene directs conversion of cardiomyocytes to genuine pacemaker cells

Study sheds light on how new treatments could be more effective in early stages of bipolar disorder

Lexicon receives FDA Fast Track status for development of LX1033 for irritable bowel syndrome

UMCG enrolls and treats first patients in RENEW pivotal trial to evaluate RePneu LVRC

IRB Barcelona, BBVA Foundation organize international conference on biostatistics

AcelRx announces top-line data from Sufentanil NanoTab PCA System Phase 3 trial

Novartis receives FDA approval for Signifor injection to treat Cushing's disease

Cempra commences CEM-102 Phase 2 trial in prosthetic joint infections

Iclusig gets FDA approval for two rare blood and bone marrow diseases

CEL-SCI net loss decreases to $17.6 million for fiscal year 2012

FDA approves Novartis Signifor injection for treatment of Cushing's disease

God will control my asthma

NovaDigm announces data from NDV-3 vaccine Phase 1 study on Candida and Staph infections

Diuretic-based antihypertensive therapy touted for obese

Doctors should use different therapies when treating older and younger patients with CLL

Eli Lilly provides update on solanezumab Phase 3 clinical study for mild Alzheimer's

Bumetanide could treat children with severe autism or Asperger's syndrome

AZD6765 briefly improves treatment-resistant patients' depression symptoms in minutes

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer